Cargando…

Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy

Patients with chronic hepatitis C have both higher prevalence of diabetes mellitus type 2 (T2DM) and increased cardiovascular risk compared to never infected people. Sustained viral response (SVR) achievement led to decreasing incidence and prevalence of T2DM during the interferon era of HCV treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Drazilova, Sylvia, Gazda, Jakub, Janicko, Martin, Jarcuska, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110000/
https://www.ncbi.nlm.nih.gov/pubmed/30186821
http://dx.doi.org/10.1155/2018/6150861
_version_ 1783350405425528832
author Drazilova, Sylvia
Gazda, Jakub
Janicko, Martin
Jarcuska, Peter
author_facet Drazilova, Sylvia
Gazda, Jakub
Janicko, Martin
Jarcuska, Peter
author_sort Drazilova, Sylvia
collection PubMed
description Patients with chronic hepatitis C have both higher prevalence of diabetes mellitus type 2 (T2DM) and increased cardiovascular risk compared to never infected people. Sustained viral response (SVR) achievement led to decreasing incidence and prevalence of T2DM during the interferon era of HCV treatment. Currently, direct-acting antiviral drugs (DAA) are the gold standard for treating HCV infection, while yielding SVR in nearly all patients. In chronic HCV patients with T2DM (prediabetes most likely too), DAA therapy is associated with both better fasting glucose and glycated hemoglobin (HbA1C) controls; thus reducing pharmacotherapy in a certain part of patients is possible. Papers mentioned in the review confirmed DAA role in both total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) increase. This alteration was accompanied by an increase in high-density lipoprotein cholesterol (HDL-C) and a decrease in triglycerides (TG) verified by most of the studies. However, the clinical significance of lipoprotein alterations caused by DAA therapy has not been explained yet. Moreover, DAA treatment of chronic hepatitis C improves hypertension control and atherosclerotic plaques. It is very likely that DAA therapeutic regimens will decrease both T2DM prevalence and cardiovascular risk in chronic hepatitis C patients; further research, however, is needed.
format Online
Article
Text
id pubmed-6110000
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-61100002018-09-05 Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy Drazilova, Sylvia Gazda, Jakub Janicko, Martin Jarcuska, Peter Can J Gastroenterol Hepatol Review Article Patients with chronic hepatitis C have both higher prevalence of diabetes mellitus type 2 (T2DM) and increased cardiovascular risk compared to never infected people. Sustained viral response (SVR) achievement led to decreasing incidence and prevalence of T2DM during the interferon era of HCV treatment. Currently, direct-acting antiviral drugs (DAA) are the gold standard for treating HCV infection, while yielding SVR in nearly all patients. In chronic HCV patients with T2DM (prediabetes most likely too), DAA therapy is associated with both better fasting glucose and glycated hemoglobin (HbA1C) controls; thus reducing pharmacotherapy in a certain part of patients is possible. Papers mentioned in the review confirmed DAA role in both total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) increase. This alteration was accompanied by an increase in high-density lipoprotein cholesterol (HDL-C) and a decrease in triglycerides (TG) verified by most of the studies. However, the clinical significance of lipoprotein alterations caused by DAA therapy has not been explained yet. Moreover, DAA treatment of chronic hepatitis C improves hypertension control and atherosclerotic plaques. It is very likely that DAA therapeutic regimens will decrease both T2DM prevalence and cardiovascular risk in chronic hepatitis C patients; further research, however, is needed. Hindawi 2018-08-13 /pmc/articles/PMC6110000/ /pubmed/30186821 http://dx.doi.org/10.1155/2018/6150861 Text en Copyright © 2018 Sylvia Drazilova et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Drazilova, Sylvia
Gazda, Jakub
Janicko, Martin
Jarcuska, Peter
Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
title Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
title_full Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
title_fullStr Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
title_full_unstemmed Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
title_short Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
title_sort chronic hepatitis c association with diabetes mellitus and cardiovascular risk in the era of daa therapy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110000/
https://www.ncbi.nlm.nih.gov/pubmed/30186821
http://dx.doi.org/10.1155/2018/6150861
work_keys_str_mv AT drazilovasylvia chronichepatitiscassociationwithdiabetesmellitusandcardiovascularriskintheeraofdaatherapy
AT gazdajakub chronichepatitiscassociationwithdiabetesmellitusandcardiovascularriskintheeraofdaatherapy
AT janickomartin chronichepatitiscassociationwithdiabetesmellitusandcardiovascularriskintheeraofdaatherapy
AT jarcuskapeter chronichepatitiscassociationwithdiabetesmellitusandcardiovascularriskintheeraofdaatherapy